EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function

Sophie Jl Brown iD, David C Briggs iD, Patrick Costello iD, Hiroko Yaguchi iD, Charles Rm Bangham iD, Peter J Parker iD, Neil Q McDonald iD

Biochemical Journal · 05.11.2025 · 482 (21) · 1659-1675

DOI: 10.1042/bcj20253384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Journal, online erschienen am 04.11.2025. Verfasst von Sophie Jl Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Protein Phosphorylation Laboratory. Hauptthemen laut MEDLINE: Protein Kinase C beta, Gain of Function Mutation, Mutation, Missense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the T-cell receptor signalling pathway have been identified in patients with adult T-cell leukaemia/lymphoma (ATLL) and one of the most frequently observed targets of these mutations is protein kinase C beta (PKCβ). Here, we have characterised the most frequent mutation in PKCβ (D427N), addressing the issue of gain/loss of function, neomorphic change and assessing the impact of mutation in vivo, in cells, biochemically and structurally. It is concluded that this mutation is a gain-of-function, activating mutation that confers an altered substrate specificity on this protein kinase. In a constitutive knock-in mouse model, this activated allele induces splenomegaly associated with extramedullary haematopoiesis. Pharmacologically, the D427N mutant protein displays poor sensitivity to established PKCβ inhibitors, necessitating the development of bespoke therapeutics for any ATLL intervention through this target. Such efforts could be guided by the availability of the D427N mutant-ruboxistaurin structure presented here.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase C betaGain of Function MutationMutation, MissenseAnimalsMiceHumansGene Knock-In Techniques

Stichwörter der Autor:innen

ATLLHTLV-1PKCβcancer associated mutation

Substanzen

Protein Kinase C betaPRKCB protein, human

Autor:innen und Institutionen

  • Protein Phosphorylation Laboratory.
  • Signalling and Structural Biology Laboratory.
  • Signalling and Transcription Laboratory, Francis Crick Institute, London, U.K.
  • Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, U.K.
  • School of Cancer and Pharmaceutical Sciences, Guy's Campus, King's College London, London, U.K.
  • Institute of Structural and Molecular Biology, School of Natural Sciences, Birkbeck College, London, U.K.

ORCID-Profile: Sophie Jl Brown, David C Briggs, Patrick Costello, Hiroko Yaguchi, Charles Rm Bangham, Peter J Parker, Neil Q McDonald

Förderung

  • Wellcome Trust

Zitieren

APA

Brown, S. J., Briggs, D. C., Costello, P., Yaguchi, H., Bangham, C. R., Parker, P. J., & McDonald, N. Q. (2025). Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function. Biochemical Journal, 482(21), 1659-1675. https://doi.org/10.1042/bcj20253384

Vancouver

Brown SJ, Briggs DC, Costello P, Yaguchi H, Bangham CR, Parker PJ, et al. Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function. Biochemical Journal. 2025;482(21):1659-1675. doi:10.1042/bcj20253384

BibTeX
@article{Brown2025,
  author = {Brown, Sophie Jl and Briggs, David C and Costello, Patrick and Yaguchi, Hiroko and Bangham, Charles Rm and Parker, Peter J and McDonald, Neil Q},
  title = {Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function},
  journal = {Biochemical Journal},
  year = {2025},
  volume = {482},
  number = {21},
  pages = {1659--1675},
  doi = {10.1042/bcj20253384}
}
Kostenlos starten →